95 results on '"Rosell, R"'
Search Results
2. Identification of AEG-1 and BARD1 as predictors of erlotinib outcome in EGFR-mutant non-small cell lung cancer (NSCLC) by NanoString multiple target profiling.
3. The nuclear factor kB (NFkB) and Notch signaling pathways and BRCA1 mRNA expression in stage IV non-small cell lung cancer (NSCLC) patients (p).
4. Screening for mutations in Colombian metastatic non-small cell lung cancer (NSCLC) patients (ONCOLGroup).
5. Initial detection of the double epidermal growth factor receptor (EGFR) mutation (L858R or deletion in exon 19 [del 19] plus T790M) in non-small cell lung cancer (NSCLC) patients (p) with brain metastases (mets) and the influence of first-line chemotherapy on outcome to erlotinib.
6. Randomized phase III trial of gemcitabine/carboplatin with or without iniparib (BSI-201) in patients with previously untreated stage IV squamous non-small cell lung cancer (NSCLC).
7. The surfactant protein B (SFTPB) as a surrogate of circulating tumor cells (CTC) with prognostic value in advanced-stage NSCLC.
8. Astrocyte elevated gene 1 (AEG-1) mRNA expression in non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations.
9. Mutations of the catalytic subunit a of PI3K (PIK3CA) in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations.
10. Survivin and CrkL expression in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations.
11. Gene expression profiles in non-small cell lung cancers (NSCLCs) and in corresponding healthy lung tissues in smokers versus nonsmokers.
12. Immunohistochemistry (IHC) with EGFR mutation-specific monoclonal antibodies (mAbs) for screening EGFR mutations in non-small cell lung cancer (NSCLC) patients (p).
13. mRNA expression of protein phosphatase 2A/C (PP2A/C) in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations.
14. Small cell lung cancer in women: The Spanish female-specific database WORLD07.
15. Expression of MET, IGF-1R, IL-6/gp130, and AXL in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations.
16. Feasibility of a prospective host cell reactivation assay (HCRA) in non-small cell lung cancer (NSCLC) patients.
17. Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) with EGFR in-frame deletions of exon 19 according to the size of the deletion.
18. BRCA1 mRNA expression and response in locally advanced esophageal cancer patients (p) treated with chemoradiotherapy.
19. Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) according to the presence of the EGFR T790M mutation and BRCA1 mRNA expression levels in pretreatment biopsies.
20. BRCA1 and RAP80 mRNA levels and median survival (MS) of advanced gastric cancer patients (p) treated with oxaliplatin plus 5-fluorouracil (FOLFOX).
21. Characteristics and outcomes of non-small cell lung cancer (NSCLC) patients (pts) carrying epidermal growth factor receptor (EGFR) mutations who progress after initial erlotinib (E) response
22. Multicenter prospective trial of customized erlotinib for advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Final results of the Spanish Lung Cancer Group (SLCG) trial
23. Blood-based CHRNA3 single nucleotide polymorphisms (SNPs) and outcome in advanced non-small cell lung cancer (NSCLC) patients (p)
24. Phase I trial of vorinostat in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations after erlotinib progression
25. Lung cancer in women: The Spanish female-specific database WORLD 07
26. Soluble vascular endothelial growth factor receptor 2 (VEGFR2): New biomarker in advanced non-small cell lung cancer (NSCLC)?
27. Detection of EGFR mutations in samples with few cancer cells in non-small cell lung cancer (NSCLC) patients (p) and distribution of exon 20 mutations
28. Cisplatin (CDDP) plus vinorelbine (NVB) as first-line treatment for advanced non-small-cell lung cancer (NSCLC): Retrospective analysis to improve the patient’s convenience on day 8 NVB administration
29. Effect of first-line treatment and CHFR and 14–3-3σ methylation status on survival to second-line chemotherapy or EGFR tyrosine kinase inhibitors (TKIs) in stage IV non-small-cell lung cancer (NSCLC)
30. Spanish Lung Adenocarcinoma Trial (SLAT) of customized treatment based on EGFR mutations (mut) and BRCA1 mRNA expression: Ancillary analyses of Abraxas and RAP80 expression
31. Predictors of long-term survival in lung cancer patients (p) included in the randomized Spanish Lung Cancer Group 0008 phase II trial using concomitant chemoradiation with docetaxel (D) and carboplatin (Cb) plus induction (I) or consolidation (C) chemotherapy (CT) with docetaxel and gemcitabine (G)
32. Influence of XPG mRNA levels on the effect of BRCA1 mRNA levels in prognosis of early non-small cell lung cancer (NSCLC)
33. BRCA1 mRNA expression in patients (p) with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy
34. Pemetrexed (P) alone or in combination with platinum for malignant pleural mesothelioma (MPM): Efficacy and toxicity of the International Expanded Access Program (EAP) in Spanish patients (p)
35. Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC)
36. Validation of 5- and 3-gene expression signatures for predicting outcome in non-small cell lung cancer (NSCLC) patients (p)
37. Spanish customized adjuvant trial (SCAT) based on BRCA1 mRNA levels
38. Use of BRCA1 mRNA expression levels to predict survival in breast cancer patients (p) treated with neoadjuvant chemotherapy
39. Erlotinib customization based on epidermal growth factor receptor (EGFR) mutations in stage IV non-small-cell lung cancer (NSCLC) patients (p)
40. Prognostic value of class III b-tubulin (TUBB3) in operable non-small cell lung cancer (NSCLC) and predictive value for adjuvant cisplatin-based chemotherapy (CT): A validation study on three randomized trials
41. Concordance and clinical value of the MGMT promoter methylation pattern in tissue with paired serum and MGMT protein expression in a series of glioblastoma (GB) patients
42. Impact in cost of new cytotoxic and biological agents for colorectal and lung cancer: A European model
43. Expression profile of 29 genes by real-time quantitative PCR (RT-QPCR) in early-stage (I-IIIA) squamous cell carcinoma of the lung (SCCL)
44. Role of ERCC1, XRCC3, Aurora A and TGFBR1 single-nucleotide polymorphisms (SNP) and CHFR and 14–3-3σ methylation in a customized cisplatin (cis) trial based on ERCC1 mRNA levels in stage IV non-small cell lung cancer (NSCLC) patients (pts)
45. XPD 312 single nucleotide polymorphism (SNP) in stage IIIA-B non-small cell lung cancer (NSCLC) patients (p) <59 years (y) treated with chemotherapy followed by surgery
46. The NATCH trial: Observations on the neoadjuvant arm
47. Cisplatin (CDDP) plus vinorelbine (VRB) as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC): Molecular correlates
48. Sex differences in non-small cell lung cancer (NSCLC) patients (p) participating in Spanish Lung Cancer Group (SLCG) trials
49. Analysis of the prognostic role of plasmatic K-ras mutations in advanced non-small cell lung cancer (NSCLC) patients
50. High correspondence between EGFR mutations in tissue and in circulating DNA form non-small-cell lung cancer (NSCLC) patients (p) with poor performance status (PS)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.